NCT01411137View on ClinicalTrials.gov

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Parkinson's Disease
Interventions
DRUG

IPX066

"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"

Trial Locations (8)

11725

Parkinson's Disease and Movement Disorders Center of Long Island, Commack

34471

Renstar Medical Research, Ocala

35233

University of Alabama at Birmingham, Birmingham

48025

Quest Research Institute, Bingham Farms

53233

Wisconsin Institute for Neurologic and Sleep Disorders, Milwaukee

89102

University of Nevada School of Medicine, Las Vegas

92037

Coastal Neurological Medical Group, La Jolla

94085

The Parkinson's Institute, Sunnyvale

Sponsors
All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Impax Laboratories, LLC

INDUSTRY

NCT01411137 - Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study | Biotech Hunter | Biotech Hunter